Key result
Tp-e interval was an independent predictor of late gadolinium enhancement on CMR in hypertrophic cardiomyopathy patients (OR 1.017; 95% CI 1.001-1.034; P=0.017).
Why the study?
The study was conducted to investigate the relationship between QTc interval, Tp-e interval, Tp-e/QTc ratio, 5-year SCD risk score, and LGE detected by CMR in HCM patients.
Does the Tp-e interval correlate with late gadolinium enhancement on CMR and 5-year sudden cardiac death risk score in patients with hypertrophic cardiomyopathy?
Cross-Sectional (n=74)
Does the Tp-e interval correlate with late gadolinium enhancement on CMR and 5-year sudden cardiac death risk score in patients with hypertrophic cardiomyopathy?
Effect estimate: OR 1.017 (95% CI 1.001-1.034)
p-value: p=0.017
The Tp-e interval on ECG is independently associated with myocardial fibrosis (LGE) on CMR and may help optimize sudden cardiac death risk stratification in patients with hypertrophic cardiomyopathy.
Tp-e interval was associated with LGE in HCM; hypothesis-generating for SCD risk stratification, should not yet change practice.
BACKGROUND: The aim of this study was to investigate the relationship between QT (QTc) interval, Tp-e interval, Tp-e/QTc ratio, 5-year sudden cardiac death (SCD) risk score, and late gadolinium enhancement (LGE) detected by CMR in hypertrophic cardiomyopathy (HCM) patients. METHOD: A total of 74 consecutive patients who underwent CMR with HCM diagnosis were included in the study. These patients were divided into two groups according to the presence of LGE on CMR. All patients underwent detailed echocardiography and QTc interval, Tp-e interval, and Tp-e/QTc ratios and 5-year SCD risk scores were calculated. These parameters were compared for two groups. RESULTS: CMR revealed LGE in 32 (43.2%) of 74 HCM patients. In the group with LGE, significantly higher QTc interval (p = 0.002), Tp-e interval (p < 0.001), Tp-e/QTc ratio (p = 0.004), and 5-year SCD risk score were detected. In addition, QTc interval, Tp-e interval, Tp-e/QTc ratio, maximum wall thickness, left ventricular mass index, 5-year SCD risk score, and cardiac fibrosis index were found to be correlated with various degrees in correlation analysis. Also, Tp-e interval is found to be an independent predictor of LGE detected by CMR in HCM patients (p = 0.017, OR [%95 CI] = 1.017 [1.001-1.034]). In addition, the Tp-e interval can detect the LGE with a sensitivity of 64.3% and a specificity of 84.2% at 99.4 ms. (p < 0.001, AUC [95% CI] = 0.790 [0.676-0.905]). CONCLUSION: The Tp-e interval can be used to optimize SCD risk stratification in HCM patients and determine which patients will benefit from implantable cardioverter-defibrillator (ICD) treatment.
No takes yet. Share an insight, caveat, or question.
Demir et al. (2019) conducted a cross-sectional in Hypertrophic cardiomyopathy (n=74). Tp-e interval was evaluated on Late gadolinium enhancement (LGE) detected by CMR (OR 1.017, 95% CI 1.001-1.034, p=0.017). Tp-e interval was an independent predictor of late gadolinium enhancement on CMR in hypertrophic cardiomyopathy patients (OR 1.017; 95% CI 1.001-1.034; P=0.017).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: